Core Insights - Alibaba Health reported a revenue of RMB 16.697 billion for the six months ending September 30, 2025, representing a year-on-year growth of 17% [1] - Gross profit reached RMB 4.184 billion, up 18.4% year-on-year, while net profit surged by 64.7% to RMB 1.266 billion [1] - Adjusted net profit was RMB 1.356 billion, reflecting a year-on-year increase of 38.7% [1] Revenue and User Growth - The number of merchants on the Tmall Health platform exceeded 56,000, with SKUs increasing by over 97 million [1] - Annual active user numbers and annualized ARPU continued to grow, with platform GMV achieving stable year-on-year growth [1] - The self-operated business revenue reached RMB 14.38 billion, marking an 18.6% increase year-on-year [1] Strategic Collaborations - Alibaba Health partnered with leading pharmaceutical companies such as Eli Lilly, AstraZeneca, and Pfizer to launch dozens of new specialty drugs [2] - The company is expanding digital health services through strategic collaborations in online retail, category expansion, and disease education [2] - Over 250,000 healthcare professionals, including licensed physicians and pharmacists, are now providing online health consultation services, an increase of over 20,000 from the previous year [2]